December 04, 2025 22:05 ET | Source: Symbotic Inc. WILMINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Symbotic Inc. (Nasdaq:…
SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…
November 08, 2025 11:45 ET | Source: Vor Biopharma Treatment with telitacicept for 39 weeks resulted in a rapid, clinically…
October 22, 2025 16:30 ET | Source: Vor Biopharma CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq:…
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to…
First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025UK Clinical Trial Application (CTA) approval shortly…